Kamada (KMDA) Other Non-Current Liabilities (2012 - 2026)
Kamada's (KMDA) quarterly Other Non-Current Liabilities came in at $29.0 million in Q2 2026, down 11.65% on a YoY basis from $32.8 million in Q2 2025, and down 3.22% quarter-over-quarter from $29.9 million in Q1 2026.
Analysis
Kamada (KMDA) Other Non-Current Liabilities (2012 - 2026) Analysis & Trends
Kamada (KMDA) has reported Other Non-Current Liabilities for 9 consecutive years, with $29.0 million the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, Other Non-Current Liabilities fell 11.65% year-over-year to $29.0 million; the trailing twelve-month figure through Jun 2026 stood at $29.0 million (down 11.65% YoY), and the FY2025 full-year result was $30.1 million, down 8.24% from the prior year.
- Other Non-Current Liabilities eased to $29.0 million in Q2 2026 per KMDA's latest filing, from $29.9 million in the prior quarter.
- Across five years, Other Non-Current Liabilities topped out at $42.5 million in Q1 2022 and bottomed at $29.0 million in Q2 2026.
- Historically, Other Non-Current Liabilities has averaged $34.9 million across 5 years, with a median of $34.3 million in 2023.
- The sharpest annual moves came in 2022 and 2025: Other Non-Current Liabilities decreased 15.07% in 2022, then retreated 4.25% in 2025.
- Over 5 years, Other Non-Current Liabilities stood at $37.3 million in 2022, then retreated by 7.85% to $34.4 million in 2023, then decreased by 4.55% to $32.8 million in 2024, then retreated by 8.24% to $30.1 million in 2025, then decreased by 3.82% to $29.0 million in 2026.
- According to Business Quant data, Other Non-Current Liabilities over the past three periods registered $29.0 million, $29.9 million, and $30.1 million for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Amgen | 211.73 Bn | 197.74 Bn | 7.24 Bn |
| 2 | Gilead Sciences | 180.92 Bn | 177.74 Bn | 6.22 Bn |
| 3 | Vertex Pharmaceuticals | 132.16 Bn | 124.30 Bn | 2.84 Bn |
| 4 | Regeneron Pharmaceuticals | 82.89 Bn | 74.90 Bn | 3.93 Bn |
| 5 | Argenx Se | 61.41 Bn | 56.23 Bn | 1.37 Bn |
| 6 | Moderna | 53.99 Bn | 48.85 Bn | 52.00 Mn |
| 7 | Alnylam Pharmaceuticals | 34.48 Bn | 31.18 Bn | 992.69 Mn |
| 8 | Biogen | 31.15 Bn | 29.86 Bn | 1.96 Bn |
| 9 | Roivant Sciences | 30.05 Bn | 30.05 Bn | 1.16 Mn |
| 10 | Kamada | 473.57 Mn | 403.43 Mn | 22.47 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 28.96 Mn |
| Mar 31, 2026 | 29.93 Mn |
| Dec 31, 2025 | 30.11 Mn |
| Sep 30, 2025 | 32.54 Mn |
| Jun 30, 2025 | 32.78 Mn |
| Mar 31, 2025 | 32.99 Mn |
| Dec 31, 2024 | 32.82 Mn |
| Sep 30, 2024 | 34.12 Mn |
| Jun 30, 2024 | 34.24 Mn |
| Mar 31, 2024 | 34.84 Mn |
| Dec 31, 2023 | 34.38 Mn |
| Sep 30, 2023 | 36.48 Mn |
| Jun 30, 2023 | 36.51 Mn |
| Mar 31, 2023 | 37.28 Mn |
| Dec 31, 2022 | 37.31 Mn |
| Sep 30, 2022 | 39.92 Mn |
| Jun 30, 2022 | 41.30 Mn |
| Mar 31, 2022 | 42.53 Mn |
| Dec 31, 2021 | 43.93 Mn |
| Dec 31, 2020 | 4.94 Mn |